Dr. Amer M. Zeidan
Claim this profileYale Cancer Center
Studies Leukemia
Studies Myelodysplastic Syndrome
14 reported clinical trials
23 drugs studied
Area of expertise
1Leukemia
TP53 positive
BCR/ABL negative
BCR/ABL positive
2Myelodysplastic Syndrome
TP53 positive
RARA positive
Affiliated Hospitals
Yale Cancer Center
Yale University
Clinical Trials Amer M. Zeidan is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Tamibarotene + Azacitidine
for Myelodysplastic Syndrome
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Recruiting1 award Phase 34 criteria
More about Amer M. Zeidan
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Amer M. Zeidan has experience with
- Azacitidine
- Venetoclax
- MBG453
- CC-90009
- Luspatercept
- SL-172154
Breakdown of trials Amer M. Zeidan has run
Leukemia
Myelodysplastic Syndrome
Preleukemia
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amer M. Zeidan specialize in?
Amer M. Zeidan focuses on Leukemia and Myelodysplastic Syndrome. In particular, much of their work with Leukemia has involved TP53 positive patients, or patients who are BCR/ABL negative.
Is Amer M. Zeidan currently recruiting for clinical trials?
Yes, Amer M. Zeidan is currently recruiting for 4 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Amer M. Zeidan has studied deeply?
Yes, Amer M. Zeidan has studied treatments such as Azacitidine, Venetoclax, MBG453.
What is the best way to schedule an appointment with Amer M. Zeidan?
Apply for one of the trials that Amer M. Zeidan is conducting.
What is the office address of Amer M. Zeidan?
The office of Amer M. Zeidan is located at: Yale Cancer Center, New Haven, Connecticut 06510 United States. This is the address for their practice at the Yale Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.